Hematology

Spondyloarthritis

Questions discussed in this category

In a patient with a Factor V Leiden heterozygous mutation but no prior thrombosis, would you consider using a JAK inhibitor for the treatment of spondyloarthritis or rheumatoid arthritis if other options have been ineffective?

1 Answer available

Papers discussed in this category

RMD open, 2022 Nov

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.

Related Topics in Hematology